BioChain has reached partnerships with NanoString and 10x Genomics to extend its spatial multiomics services.
BioChain Institute, a supplier of biosample products and services, recently announced the extension of its spatial multiomics services via partnerships with NanoString Technologies and 10X Genomics. NanoString is a biotechnology company specializing in technology and translational research solutions, while 10X Genomics is a biotechnology company focused on gene sequencing technology.
According to an April 18, 2023 press release, spatial profiling is a technique that reveals the spatial context of RNA and proteins in tissue. BioChain spatial profiling technology uses a three-step process: selecting tissue samples, working with spatial biology scientists to determine which spatial path to use, and running the customized spatial process.
“Our partnerships, combined with our in-house services, make us a full-service provider of spatial biology services,” said Vidyodhaya Sundaram, vice-president of Business Development, BioChain, in the release. “With the technologies now available from BioChain, you can spatially resolve the entire transcriptome or high-plex protein across your tissue sample.”
“Our technology’s advantages include its high multiplexing ability, low hands-on time, and a straightforward procedure,” continued Sundaram. “Our goal is to bring this specialized technology to any researcher or biomedical professional who wants to use it.”
Source: BioChain Institute
British Patient Capital Invests £10 Million in Maxion Therapeutics, Part of Series A Financing Round
March 27th 2025The £10 million (US$13 million) investment is part of a larger £58 million (US$75 million) Series A financing round to be used for the development of Maxion Therapeutics’ preclinical lead program for treating inflammatory diseases.